http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
-
ILMN FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
-
Illumina (ILMN) Expand Collaboration with Janssen for Molecular Residual Disease Cancer Test
-
Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
-
Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
-
The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk
-
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – ILMN
-
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
Illumina To Webcast Upcoming Investor Conference
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
Illumina (ILMN) to divest Grail
-
Illumina Announces Decision to Divest GRAIL
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
Illumina (ILMN) submits Form 10 to the Securities and Exchange Commission related to its potential divestiture of GRAIL
-
Illumina submits Form 10 to the Securities and Exchange Commission
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Illumina, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ILMN
-
Illumina To Webcast Upcoming Investor Conferences
-
Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries
-
Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023
-
Veracyte (VCYT) Announces In Vitro Diagnostic Agreement with Illumina (ILMN) to Broaden Availability of Its Tests for Patients Globally
-
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
-
Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors
-
Illumina (ILMN) responds to European Commission's divestiture order
-
Illumina responds to European Commission's divestiture order
-
Illumina Posted a Stewardship-Focused Presentation for Investors
-
Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023
-
Illumina (ILMN) Appoints Jacob Thaysen as CEO
-
Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina (ILMN) Announces Solutions Center in India
-
Illumina expands genomics capabilities in India with opening of Solutions Center
-
Illumina To Webcast Upcoming Investor Conference
-
Illumina (ILMN) Appoints Steven Barnard as CTO
-
Dr. Steven Barnard Appointed Chief Technology Officer
-
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023
-
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
-
Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options
-
Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
-
The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck
-
Illumina (ILMN) Launches DRAGEN 4.2
-
Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery
-
Illumina releases 2022 Corporate Social Responsibility Report
-
Illumina's (ILMN) Board of Directors elects two experienced Independent Directors to Board
-
Illumina's Board of Directors elects two experienced Independent Directors to Board
-
Illumina (ILMN) unveils AI software to predict disease-causing genetic mutations in patients
-
Illumina unveils AI software to predict disease-causing genetic mutations in patients
-
Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023
-
Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing
-
Pluton Biosciences Raises $16.5M Series A led by Illumina Ventures and RA Capital to discover and deploy microbes that will fight climate change
